Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.42 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221303 | 0.92 | IGF1R (0.47) | IGF1RCCNA2CDK2CCNA1PAK1 | |
| SCHEMBL13221282 | 0.90 | IGF1R (0.51) | IGF1RCCNA2CDK2CCNA1PAK1 | |
| SCHEMBL13221294 | 0.90 | IGF1R (0.49) | IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL13221297 | 0.89 | IGF1R (0.43) | IGF1RCCNA2CDK2CCNA1PAK1 | |
| SCHEMBL13221288 | 0.89 | CCNA2 (0.44) | IGF1RCCNA2CDK2CCNA1PAK1 | |
| SCHEMBL13221304 | 0.88 | AURKB (0.41) | CCNA2CDK2CCNA1SRCGSK3B | |
| SCHEMBL13221285 | 0.87 | IGF1R (0.49) | IGF1RCCNA2CDK2CCNA1PAK1 | |
| SCHEMBL13221291 | 0.86 | IGF1R (0.53) | IGF1RCCNA2CDK2CCNA1SRC | |
| SCHEMBL13221237 | 0.86 | SRC (0.44) | IGF1RCCNA2CDK2CCNA1SRC | |
| SCHEMBL13221283 | 0.85 | IGF1R (0.45) | IGF1RCCNA2CDK2CCNA1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | IGF1R 787/4885CCNA2 703/4885CDK2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.